Cost Effectiveness [qnco]
LOPINAVIR/RITONAVIR [orch, phsu]
Tablets [bodm]
Compared [acty]
Atazanavir [orch, phsu]
Ritonavir [orch, phsu]
Patients [podg]
France [geoa]
Italy [geoa]
Spain [geoa]
Objective [inpr]
Antiretroviral therapy [topp]
Patients [podg]
Balancing [orgf]
Multiple [qnco]
Including [ftcn]
Efficacy [qlco]
Adverse event [fndg]
Resistance [menp]
Concerns [idcn]
Cost Effectiveness [qnco]
Expected [idcn]
Budget [inpr]
IMPACT [gngm]
Efficacy [qlco]
Regimen [topp]
Controlled Clinical Trial [inpr]
considered [idcn]
Light [npop]
short [qlco]
economic impacts [qnco]
System, Health Care [hcro]
IMPACT [gngm]
Based [ftcn]
Drug Costs [qnco]
Cost [qnco]
Reported [inpr]
adverse effects [ftcn]
Regimen [topp]
Likelihood [qnco]
Contributing [acty]
Viral resistance [biof]
Second Line Therapy [topp]
Marginal [spco]
Cost [qnco]
health care resources [qnco]
coronary heart disease [dsyn]
Concern [idcn]
Antiretroviral therapy [topp]
Coronary heart disease risk [inpr]
Reported [inpr]
regimens [inpr]
Heart disease [dsyn]
condition [dsyn]
Study [mnob]
Set [menp]
Out [spco]
Estimate [qnco]
Long-Term Effects [phpr]
Combined [qlco]
HIV disease [dsyn]
coronary heart disease [dsyn]
Quality [qlco]
Adjusted [ftcn]
Survival [acty]
Health Care Cost [qnco]
Patients [podg]
Spain [geoa]
Italy [geoa]
France [geoa]
Methods [inpr]
Update [tmco]
Cost [qnco]
estimates [qnco]
Countries [geoa]
Supplement [food]
Framingham [inpr]
Coronary heart disease risk [inpr]
Equation [cnce]
Average [qnco]
Aged [orga]
baseline [bodm]
Coronary heart disease risk [inpr]
Patients [podg]
Started [qlco]
LOPINAVIR/RITONAVIR [orch, phsu]
Ritonavir [orch, phsu]
Boost [ftcn]
Atazanavir [orch, phsu]
ATV [orch, phsu]
RTV [orch, phsu]
Protease Inhibitor [bacs, phsu]
Clinical Trial [resa]
Local [spco]
Drug Costs [qnco]
AIDS [dsyn]
coronary heart disease [dsyn]
Cost [qnco]
estimates [qnco]
Estimate [qnco]
Therapies [topp]
LOPINAVIR/RITONAVIR [orch, phsu]
ATV [orch, phsu]
RTV [orch, phsu]
depend [medd]
Country [geoa]
Cost [qnco]
Structure [spco]
drug efficacy [qlco]
Benefit [qnco]
Patients [podg]
Quality [qlco]
Adjusted [ftcn]
Life [idcn]
months [tmco]
Reticular [spco]
Gain [qnco]
Subtract [inpr]
Quality-Adjusted Life Years [tmco]
Lost [ftcn]
Coronary heart disease risk [inpr]
Addition [ftcn]
Cost [qnco]
Savings [qnco]
Element [elii]
Element [elii]
IMPACT [gngm]
Range [qnco]
Cost [qnco]
Element [elii]
France [geoa]
Cost [qnco]
Save [mcha]
Element [elii]
Spain [geoa]
Incremental [qnco]
Cost Effectiveness [qnco]
Ratio [qnco]
Range [qnco]
Dominant [ftcn]
Spain [geoa]
Element [elii]
QALY [tmco]
Italy [geoa]
LOPINAVIR/RITONAVIR [orch, phsu]
Highly [qlco]
Cost Effectiveness [qnco]
Regimen [topp]
Relative [famg]
ATV [orch, phsu]
RTV [orch, phsu]
treatment [ftcn]
HIV [virs]
Countries [geoa]
Examined [fndg]
Study [mnob]
LOPINAVIR/RITONAVIR [orch, phsu]
Coronary heart disease risk [inpr]
Minimal [qlco]
Compared [acty]
Increased [qnco]
AIDS [dsyn]
Projected [inpr]
Efficacy [qlco]
Protease Inhibitor [bacs, phsu]
Based [ftcn]
Regimen [topp]
Cost [qnco]
Lipid lowering drug [phsu]
treatment [ftcn]
coronary heart disease [dsyn]
Compared [acty]
Cost Savings [qnco]
LOPINAVIR/RITONAVIR [orch, phsu]
therapy [ftcn]
choice [inbe]
Regimen [topp]
Patients [podg]
Based [ftcn]
Regimen [topp]
Expected [idcn]
Efficacy [qlco]
Countries [geoa]
Cost [qnco]
Structure [spco]
Examined [fndg]
